<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04525573</url>
  </required_header>
  <id_info>
    <org_study_id>CP20-01</org_study_id>
    <nct_id>NCT04525573</nct_id>
  </id_info>
  <brief_title>Effects of a Red/Gold/IR LED Combination Light on Reduction of Fat</brief_title>
  <official_title>Effects of a Red/Gold/IR LED Combination Light on Reduction of Fat</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ward Photonics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ward Photonics LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label evaluation of the effects of a red/gold/IR LED combination light on reduction&#xD;
      of fat. The results shall be compared to previous results from a comparator device utilizing&#xD;
      only red LED monotherapy for the non-invasive reduction in fat layer for body contouring.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The combination of gold/red/IR light is theorized to enhance the effect of the deeper&#xD;
      penetrating red/IR light with the photomodulated effects of gold light. The light is&#xD;
      positioned alongside the patient as they lay, or sit on a treatment table. A light panel is&#xD;
      mounted to an articulating arm for positioning the light at the correct treatment position&#xD;
      above the patient (non-contact). The effects of a red/gold/IR combination LED light therapy&#xD;
      device on circumferential reduction of fat will be measured, and the overall health of the&#xD;
      patients will be monitored using blood tests.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 7, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Fat Reduction</measure>
    <time_frame>15 days</time_frame>
    <description>Circumferential reduction of fat as measured around the observation areas of the body.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>General Health Improvement</measure>
    <time_frame>15 days</time_frame>
    <description>The secondary outcome of this study is to monitor patient health changes during the treatment period. The principal method for monitoring patient health is through blood testing. There is some evidence in literature that patients undergoing fat reduction benefit from secondary effects associated with their general health.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Body Image</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LLLT Combination Red/Gold/IR Therapy</intervention_name>
    <description>Three LLLT combination treatments per week over the course of two consecutive weeks, and a final follow up on day-15 (total of 7 treatments).</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood Testing:&#xD;
&#xD;
        -  Glucose&#xD;
&#xD;
        -  CMP&#xD;
&#xD;
        -  A1c&#xD;
&#xD;
        -  Fructosamine&#xD;
&#xD;
        -  Lipids&#xD;
&#xD;
        -  Leptin&#xD;
&#xD;
        -  CRP&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Men and women over the age of 18 and with diagnosed Type 2 diabetes who are seeking fat&#xD;
        loss.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Study participant is 18 years of age or older.&#xD;
&#xD;
          -  Diagnosed with adult-onset (type 2) diabetes.&#xD;
&#xD;
          -  Obesity&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Photosensitive condition or medication.&#xD;
&#xD;
          -  Active chemotherapy treatment or other cancer treatment.&#xD;
&#xD;
          -  Pregnant, possibly pregnant or planning pregnancy prior to the end of study&#xD;
             participation.&#xD;
&#xD;
          -  Developmental disability or cognitive impairment that, in the opinion of the&#xD;
             investigator, would preclude adequate comprehension of the informed consent form&#xD;
             and/or ability to record the necessary study measurements.&#xD;
&#xD;
          -  Chronic stomach conditions (IBS, Crohn's, Ulcerative Colitis, etc.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahsaraf Dabawala, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Horizon Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahsaraf Dabawala, MD</last_name>
    <phone>847.490.0600</phone>
    <email>dabawala@aol.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Horizon Medical Center</name>
      <address>
        <city>Schaumburg</city>
        <state>Illinois</state>
        <zip>60173</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asharaf Dabawala, MD</last_name>
      <phone>847-490-0600</phone>
      <email>dabawala@aol.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Opel DR, Hagstrom E, Pace AK, Sisto K, Hirano-Ali SA, Desai S, Swan J. Light-emitting Diodes: A Brief Review and Clinical Experience. J Clin Aesthet Dermatol. 2015 Jun;8(6):36-44. Review.</citation>
    <PMID>26155326</PMID>
  </reference>
  <reference>
    <citation>Lee SY, Park KH, Choi JW, Kwon JK, Lee DR, Shin MS, Lee JS, You CE, Park MY. A prospective, randomized, placebo-controlled, double-blinded, and split-face clinical study on LED phototherapy for skin rejuvenation: clinical, profilometric, histologic, ultrastructural, and biochemical evaluations and comparison of three different treatment settings. J Photochem Photobiol B. 2007 Jul 27;88(1):51-67. Epub 2007 May 1.</citation>
    <PMID>17566756</PMID>
  </reference>
  <reference>
    <citation>Goldberg DJ, Amin S, Russell BA, Phelps R, Kellett N, Reilly LA. Combined 633-nm and 830-nm led treatment of photoaging skin. J Drugs Dermatol. 2006 Sep;5(8):748-53.</citation>
    <PMID>16989189</PMID>
  </reference>
  <reference>
    <citation>Sadick NS. A study to determine the efficacy of a novel handheld light-emitting diode device in the treatment of photoaged skin. J Cosmet Dermatol. 2008 Dec;7(4):263-7. doi: 10.1111/j.1473-2165.2008.00404.x.</citation>
    <PMID>19146602</PMID>
  </reference>
  <reference>
    <citation>Baez F, Reilly LR. The use of light-emitting diode therapy in the treatment of photoaged skin. J Cosmet Dermatol. 2007 Sep;6(3):189-94.</citation>
    <PMID>17760698</PMID>
  </reference>
  <reference>
    <citation>Russell BA, Kellett N, Reilly LR. A study to determine the efficacy of combination LED light therapy (633 nm and 830 nm) in facial skin rejuvenation. J Cosmet Laser Ther. 2005 Dec;7(3-4):196-200.</citation>
    <PMID>16414908</PMID>
  </reference>
  <reference>
    <citation>Lee SY, You CE, Park MY. Blue and red light combination LED phototherapy for acne vulgaris in patients with skin phototype IV. Lasers Surg Med. 2007 Feb;39(2):180-8.</citation>
    <PMID>17111415</PMID>
  </reference>
  <reference>
    <citation>Goldberg DJ, Russell BA. Combination blue (415 nm) and red (633 nm) LED phototherapy in the treatment of mild to severe acne vulgaris. J Cosmet Laser Ther. 2006 Jun;8(2):71-5.</citation>
    <PMID>16766484</PMID>
  </reference>
  <reference>
    <citation>Sadick N. A study to determine the effect of combination blue (415 nm) and near-infrared (830 nm) light-emitting diode (LED) therapy for moderate acne vulgaris. J Cosmet Laser Ther. 2009 Jun;11(2):125-8. doi: 10.1080/14764170902777349.</citation>
    <PMID>19391058</PMID>
  </reference>
  <reference>
    <citation>Kwon HH, Lee JB, Yoon JY, Park SY, Ryu HH, Park BM, Kim YJ, Suh DH. The clinical and histological effect of home-use, combination blue-red LED phototherapy for mild-to-moderate acne vulgaris in Korean patients: a double-blind, randomized controlled trial. Br J Dermatol. 2013 May;168(5):1088-94. doi: 10.1111/bjd.12186.</citation>
    <PMID>23278295</PMID>
  </reference>
  <reference>
    <citation>Ablon G. Combination 830-nm and 633-nm light-emitting diode phototherapy shows promise in the treatment of recalcitrant psoriasis: preliminary findings. Photomed Laser Surg. 2010 Feb;28(1):141-6. doi: 10.1089/pho.2009.2484.</citation>
    <PMID>19764893</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 20, 2020</study_first_submitted>
  <study_first_submitted_qc>August 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2020</study_first_posted>
  <last_update_submitted>August 20, 2020</last_update_submitted>
  <last_update_submitted_qc>August 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The study is an open-label evaluation of the effects of a red/gold/IR LED combination light on reduction of fat. And general health of the patients will be monitored as a possible correlation with fat reduction. However, the findings from this study are intended to explore whether a larger comparative study should be conducted.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

